Drug intelligence / Profile preview

N2-[(benzyloxy)carbonyl]-n1-[(3S)-1-cyanopyrrolidin-3-yl]-l-leucinamide

Development stage
Unknown
Modality
Small Molecules
01

Overview

N2‑[(benzyloxy)carbonyl]‑n1‑[(3S)‑1‑cyanopyrrolidin‑3‑yl]‑L-leucinamide is a synthetic small molecule belonging to the n-acyl-alpha amino acids and derivatives class. It is characterized by an acylated alpha-amino acid structure, specifically a leucine derivative with benzyloxycarbonyl and cyanopyrrolidine substituents. This compound is known as an experimental inhibitor of cathepsin K, a lysosomal cysteine protease involved in bone resorption and other physiological processes. Cathepsin K inhibitors have been investigated for potential therapeutic use in osteoporosis and other diseases involving excessive bone degradation, but this specific compound has not advanced beyond early experimental stages[2][5][1].

Other names
N2-((benzyloxy)carbonyl)-n1-((3S)-1-cyanopyrrolidin-3-yl)-l-leucinamidebenzyl N-[(1S)-1-{[(3R)-1-cyanopyrrolidin-3-yl]carbamoyl}-3-methylbutyl]carbamatebenzyl N-((1S)-1-( ( ( 3R ) - 1-cyanopyrrolidin - 3 - yl ) carbamoyl ) - 3-methylbutyl ) carbamate
02

Targets

CTSK (Cathepsin K)

Beyond the preview

Go deeper on N2-[(benzyloxy)carbonyl]-n1-[(3S)-1-cyanopyrrolidin-3-yl]-l-leucinamide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on N2-[(benzyloxy)carbonyl]-n1-[(3S)-1-cyanopyrrolidin-3-yl]-l-leucinamide.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call